MATT TINDALL, MBA
Mr. Tindall has extensive leadership experience as a Board Chairman, CEO, Executive and Founder of life sciences companies across multiple therapeutic modalities and domains including, rare disease, cardiovascular disease, neurology, oncology, infectious disease and bioinformatics. Over the past two decades, Mr. Tindall led teams at Fabric Genomics (acquired by GeneDx), IMS Health (now IQVIA), Digitas […]
MARK DE SOUZA, PhD
Dr. de Souza has deep experience in creating and developing virtual biotechnology companies. He has participated as a CEO/Executive Chairman/Co-Founder of NFlection Therapeutics, Chromaderm, SeylanMed, PellePharm, MyoTherix, Lotus Tissue Repair, and others. Mark has spent 15+ years in the rare disease, neurology and dermatology spaces.
Paul Eckburg, MD
Paul Eckburg, M.D. is an Infectious Diseases physician and Chief Medical Officer of Flightpath and has worked in clinical research and anti-infective drug development for over 26 years. Dr. Eckburg has served as CMO for Zavante Therapeutics, Geom Therapeutics, Utility Therapeutics, Bugworks Research, AN2 Therapeutics, and NovoBiotic, among others. He has been involved in the […]
COLLEEN JOHNSON, MSc, DABT
Colleen Johnson, M.S., D.A.B.T is a board-certified toxicologist who has been working with small- to mid-sized pharmaceuticals companies for more than 20 years. Her focus has primarily been in small molecule development for a broad range of indications. She is involved in providing toxicology expertise for all phases of development from early discovery to NDA […]
CHRIS PHILLIPS, MS
Chris Phillips has over 4 decades of pharmaceutical CMC experience ranging from R&D to cGMP manufacturing for small molecules, native proteins and biotechnology drug substances and drug products. Previously, Chris was Vice President of Formulation Development and Manufacturing at Aclaris Therapeutics, Inc. He led CMC activities related to the FDA approvals for 2 BLAs and […]
KATIE ROSENGRANT, RAC-DRUGS
Katie Rosengrant, RAC-Drugs has experience in regulatory affairs, project management, and operations for early-stage biotech companies. Her background includes contributions to IND submissions as well as coordination of grant applications, reporting requirements, and other cross-functional deliverables in oncology, infectious disease, and rare disease.
Nicole Luosey, PMP
Ms. Luosey has over 25 years of experience in product strategy, development operations, corporate planning, and program execution across multiple therapeutic areas and modalities, building program and alliance management functions supporting assets at every stage of drug development. Most recently, Ms. Luosey served as Senior Vice President, Product and Development Operations at Anokion, leading cross-functional […]
